Piramal Pharma Limited (PPLPHARMA)

Name: Piramal Pharma Limited (PPLPHARMA) — historial de estados financieros
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.

Healthcare · Wall Street (EE. UU.) · Última actualización: 2026-09-20

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities.

Cifras clave

Capitalización bursátil: ₹276 billion
Ingresos (ejercicio cerrado en 2026-03-31): ₹87.6B
Beneficio neto: (₹3.3B)
Margen bruto: 59.1%
Margen neto: -3.7%

Ver gráficos interactivos y estados completos →

Cuenta de resultados anual

Cuenta de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Ingresos totales	₹87.6B	₹90.6B	₹81.1B	₹70.3B	—
Beneficio bruto	₹51.8B	₹54.9B	₹48.5B	₹40.3B	—
Ingresos operativos (EBIT)	₹1.5B	₹6.8B	₹4.6B	(₹480M)	—
Ingresos netos	(₹3.3B)	₹911M	₹178M	(₹1.9B)	—

Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.

Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de PPLPHARMA. /companies/us/PPLPHARMA

Empresas similares

La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.

English version →Todas las acciones

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.